Effect of Parecoxib on Post-craniotomy Pain

Overview

Aim of this trial: To investigate whether post-craniotomy analgesia with (i) intravenous (IV) parecoxib plus intravenous paracetamol is superior to (ii) intravenous paracetamol alone. Study Hypothesis: Post-operative analgesia with intravenous parecoxib in combination with intravenous paracetamol will be superior to intravenous paracetamol alone.

Full Title of Study: “Phase Four Study of Intravenous Parecoxib on Post-craniotomy Pain”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: December 2008

Detailed Description

Neurosurgical patients undergoing brain procedures (craniotomy patients) are known to suffer moderately severe postoperative pain and high rates of post-operative nausea and vomiting. Post-craniotomy pain is poorly treated with more than 50% of craniotomy patients experiencing postoperative pain of moderate or severe intensity. Fear of drug complications such as sedation, respiratory depression, seizures and intracranial bleeding has inhibited prescribing of effective pain treatment.Non-steroidal anti-inflammatory drugs (NSAIDS) are known to be effective analgesics in the peri-operative period however there use in cranial neurosurgery has been limited due to risk of bleeding. Parecoxib is an injectable form of NSAID that works through inhibiting cyclo-oxygenase type-2 (COX-2). The main benefit of COX-2 inhibitors is that they have minimal inhibition of platelet function and therefore minimal risk of increased bleeding.This project aims to evaluate whether parecoxib is an effective pain reliever (analgesic) after brain surgery. Patients aged 18-65 years presenting for elective craniotomy will be randomly allocated to two different analgesic programs (i) IV parecoxib and IV paracetamol or (ii) IV paracetamol. All patients will receive a standardised anaesthetic. Scalp infiltration, using 20mls of local anesthetic (bupivacaine 0.5% with adrenaline), will occur prior to skin incision. Intermittent morphine administration will used post-operatively to ensure adequate analgesia in each arm of the trial. Immediate post-operative adjunctive analgesia will be provided with nurse administered IV morphine in the post-anaesthetic care unit (PACU) as per protocol (RMH protocol for opioid titration), followed by patient controlled analgesia (PCA) morphine once the verbal rating scale is < 4 (rating out of ten). A score of less than four is considered to be mild pain. PCA will be continued for the first twenty-four hours then discontinued. Patients will then receive strict oral paracetamol and nurse administered IV morphine as required. The primary study endpoint will be morphine consumption in the first 24 hours. Data will be analysed on an intention to treat basis. Continuous variables will be graphed to determine their distribution. Normally distributed variables will be described using mean and standard deviation and compared using Student's t-tests. Skewed variables will be described using median and range (or interquartile range) and compared using Wilcoxon rank sum tests. A p-value les than 0.05 will be considered statistically significant.

Interventions

  • Drug: Intravenous Parecoxib (‘Dynastat’ Pfizer)
    • parecoxib or placebo

Arms, Groups and Cohorts

  • Placebo Comparator: 1
    • placebo (2 ml normal saline) administered intravenously at dural closure during craniotomy
  • Active Comparator: 2
    • parecoxib 40 mg in 2 ml normal saline administered intravenously at dural closure during craniotomy

Clinical Trial Outcome Measures

Primary Measures

  • Morphine consumption in 24 hour period.
    • Time Frame: 24 hours after surgery

Secondary Measures

  • Immediate post-operative hypertension (first 2 hours)
    • Time Frame: 24 hours after surgery
  • Pain scores at zero (time of extubation), 1, 2, 4, 12, 24 hours post operatively
    • Time Frame: 24 hours after surgery
  • Analgesic efficacy at 24 hours
    • Time Frame: 24 hours after surgery
  • Incidence of post-operative nausea and vomiting (first 24 hours)
    • Time Frame: 24 hours after surgery
  • Sedation or respiratory depression (first 24 hours)
    • Time Frame: 24 hours after surgery
  • Safety Monitoring (Serious adverse side effects)
    • Time Frame: 24 hours after surgery
  • Post-operative AMI
    • Time Frame: 24 hours after surgery
  • Post-operative renal failure
    • Time Frame: 24 hours after surgery
  • Post-operative thromboembolic stroke
    • Time Frame: 24 hours after surgery
  • Post-operative intracranial haemorrhage
    • Time Frame: 24 hours after surgery

Participating in This Clinical Trial

Inclusion Criteria

  • Supratentorial craniotomy, glasgow coma scale 15 Exclusion Criteria:

  • Chronic pain, – Chronic opioid use. – History of significant alcohol or benzodiazepine (BZD) use, – Inability to speak English, – Pre-operative aphasia or dysphasia, – Renal impairment (Creatinine level > 0.1), – Asthma (or evidence of reversible airway obstruction, – Known ischaemic heart disease or cerebrovascular disease, – American Society of Anaesthesiologists (ASA) grade IV or V, – Allergy to any study drug (paracetamol, parecoxib, sulphas, morphine, bupivacaine, propofol, remifentanil; – Administration of oral paracetamol within previous 8 hours. – Pregnancy or breastfeeding

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Melbourne Health
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Daryl L Williams, MBBS, Principal Investigator, Director of Anaesthesia, Royal Melbourne Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.